Claims for Patent: 9,499,545

Summary for Patent: 9,499,545

Title:	Piperidinone carboxamide azaindane CGRP receptor antagonists
Abstract:	The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Inventor(s):	Bell; Ian M. (Harleysville, PA), Fraley; Mark E. (North Wales, PA), Gallicchio; Steven N. (Horsham, PA), Ginnetti; Anthony (Perkasie, PA), Mitchell; Helen J. (Richboro, PA), Paone; Daniel V. (Lansdale, PA), Staas; Donnette D. (Harleysville, PA), Wang; Cheng (Fort Washington, PA), Zartman; C. Blair (Hatfield, PA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	14/485,259
Patent Claims:	1. A compound of Formula I: ##STR00053## or a pharmaceutically acceptable salt thereof, wherein: X is --C(R.sup.8).dbd., wherein R.sup.8 is hydrogen, F or CN; R.sup.1 is selected from the group consisting of: C.sub.1-4alkyl, cyclopropylmethyl, cyclobutylmethyl and [1-(trifluoromethyl)cyclopropyl]methyl, each of which is optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of: F and hydroxy; R.sup.2 is selected from hydrogen and methyl; and wherein: when R.sup.2 is hydrogen then R.sup.3 is selected from hydrogen, F or Cl; R.sup.4 is selected from hydrogen, F or Cl; R.sup.5 is hydrogen; R.sup.6 is selected from hydrogen or F; and R.sup.7 is selected from hydrogen, F or Cl; except that at least two of R.sup.3, R.sup.4, R.sup.6 and R.sup.7 must be F or Cl unless R.sup.3 is F in which case R.sup.4, R.sup.6 and R.sup.7 may all be hydrogen; and with the proviso that if R.sup.4 is Cl then R.sup.7 cannot be Cl; when R.sup.2 is methyl then R.sup.3 is selected from hydrogen, methyl, F, Cl, or Br; R.sup.4 is selected from hydrogen, methyl, F or Cl; R.sup.5 is selected from hydrogen or F; R.sup.6 is selected from hydrogen or F; and R.sup.7 is selected from hydrogen, methyl, F or Cl; except that if R.sup.5 is F then at least three of R.sup.3, R.sup.4, R.sup.6 and R.sup.7 must be F; and with the proviso that if R.sup.4 is methyl or Cl then R.sup.7 cannot be methyl or Cl. 2. A pharmaceutical composition which comprises an inert carrier and the compound of claim 1, or a pharmaceutically acceptable salt thereof. 3. A method of treating migraine in a mammalian patient in need of such treatment, which comprises administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.